64 results about "Muscle loss" patented technology

The invention provides methods for treating muscle loss in an individual. In one embodiment, the invention includes administering to an individual an effective amount of a branched chain amino acid (BCAA), a BCAA precursor, a BCAA metabolite, a BCAA-rich protein, a protein manipulated to enrich the BCAA content or any combination thereof. The invention further provides nutritional products for such administration, including orally-administrable nutritional products

This invention provides: 1) a method of treating a subject suffering from a muscle wasting disorder; 2) a method of preventing a muscle wasting disorder in a subject; 3) a method of treating, preventing, suppressing, inhibiting or reducing muscle loss in a subject suffering from a muscle wasting disorder; 4) a method of treating, preventing, inhibiting, reducing or suppressing muscle wasting in a subject suffering from a muscle wasting disorder; and / or 5) a method of treating, preventing, inhibiting, reducing or suppressing muscle protein catabolism in a subject suffering from a muscle wasting disorder, by administering to the subject a selective androgen receptor modulator (SARM) and / or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.

This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory loss, benign prostate hyperplasia and / or prostate cancer, by administering to the subject a selective androgen receptor modulator (SARM) compound and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, pro-drug, polymorph, crystal, or any combination thereof.

The present invention relates to pharmaceutical agents which are agents for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; the pharmaceutical agents frailty suppressants, muscle strength enhancers, muscle increasing agents, cachexia suppressants, body weight decrease suppressants, agents for the prophylaxis or treatment of prostate hypertrophy, amyotrophy or muscle loss caused by a disease or an agent for reducing the prostate weight.The present invention also relates to methods for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis in a mammal, which comprises administering an effective amount of the pharmaceutical agents of the present invention or a prodrug thereof; use of the pharmaceutical agents of the present invention or a prodrug thereof for the production of an agent for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis; and the like.

Disclosed herein are methods of treating and preventing muscle loss using ornithine in combination with at least one of phenyl acetate and phenylbutyrate.

The present invention provides a full-nutrient food formula containing short peptides for populations with muscle attenuation syndromes. The formula food with a special medical use is prepared from the food-derived short peptides as a main raw material, contains concentrate extracts of traditional medibly and edibly homogenous Chinese herbal medicines of coix seeds, semen ziziphi spinosae, mulberries, apricot kernels, white hyacinth beans, licorice, etc., and then combines calcium beta-hydroxy-beta-methylbutyrate, creatine, oligosaccharides, various vitamins and minerals to form the compound formula. The formula can be used to prepare powdery or granular or liquid food. The food prepared according to the formula can provide high-quality proteins, vitamins and minerals required for the populations with the muscle attenuation syndromes in time, does not increase liver and kidney burdens, and at the same time, can significantly increase muscle strength and LBM, increase protein synthesis,prevent muscle loss and atrophy, inhibit muscle protein degradation, and protect muscle tissues. The provided formula food containing the short peptides with the special medical use is suitable for the populations with the muscle attenuation syndromes.

The present invention concerns the methods and compositions involving nucleic acids with long repeat sequences. In some embodiments of the invention, there are methods for generating such a nucleic acid, and in other methods, there are methods for using such a nucleic acid to screen for candidate therapeutic compounds. Furthermore the present invention relates to methods of screening for Notch inhibitors and other substances that may be used to treat muscle loss and wasting.

The present invention relates to herbal-derived compositions comprising extracts of polysaccharides and carotenoids from Goji species for management of ocular disorders, diabetes, bone metabolism, arthritis, muscle loss, cardiovascular disorders, immunological disorders, fatigue, body weight, sexual disorders, aging disorders, dermatological disorders and neurological disorders. Further provided are methods for making the compositions, and methods for treating subjects with various adverse health conditions with therapeutically or health-promotionally effective amounts of the compositions.

An apparatus to treat progressive bone and muscle loss by applying vibrational and radiant energy to a human body. The vibrational energy is preferably applied by a vibrational platform that transmits gentle, dynamic, repetitive vibrations to the soles of the feet. The radiant energy is preferably provided by a bed or tanning booth that emits ultraviolet radiation.

The invention provides a high-satiety nutritious meal replacement food and a preparation method thereof. The problems that an existing meal replacement food is poor in satiety and people are very starving after eating are solved. The food comprises water-soluble dietary fibers, water-insoluble dietary fibers, L-carnitine, unsaturated fatty acid, high-quality protein, various vitamins and minerals.A slow-release technology is adopted in the food. The food is rich in various dietary fibers and low in energy, is compounded with the L-carnitine, and has the triple weight reducing effect. According to the slow-release technology, the satiety of the dietary fibers after water absorption and expansion can reach 4 hours or longer, so that energy intake is effectively reduced, and the weight reducing effect is ensured; the energy is low, in-vivo fat decomposition and energy release are promoted, and the weight reducing effect is further ensured; the L-carnitine can accelerate in-vivo fat combustion and accelerate the weight reducing process; the unsaturated fatty acid can effectively reduce the cholesterol and triglyceride level in blood; the high-quality protein can prevent the muscle loss; various vitamins and minerals can promote energy metabolism and improve the weight reducing efficiency.

The invention provides novel Wnt polypeptides that have improved production characteristics, solubility, systemic delivery, and tissue uptake, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and / or promoting muscle hypertrophy and growth.

The present invention concerns a tryptophan metabolite chosen from kynurenic acid, anthranilic acid, quinolinic acid, picolinic acid, quinaldic acid and the mixtures of same or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt of same, for use as a drug intended for increasing and / or maintaining muscle mass and / or strength in a mammal,and in particular intended for treating and / or preventing muscle atrophy in mammals and / or for promoting muscle growth in mammals doing exercise and aiming to increase muscle mass and / or quality and / or strength, for preventing the appearance of symptoms of sarcopenia or for rehabilitation following muscle loss and / or for improving recovery time after an intense physical effort.

The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and / or promoting muscle hypertrophy and growth.

Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and / or low DHEA or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and a selective estrogen receptor modulator (SERM) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, Alzheimer's disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

Systems and methods for exerting forces on a body, including a support structure defining a space and a plurality of surface contacting units that are configured to exert force upon the body, such that the weight is distributed away from the primary weight bearing regions to non-weight bearing regions of the body, or vice versa, without exerting significant shear or frictional forces on surfaces of the body. The systems and methods may be used to exert forces to cause fluid shift in different compartments of the body. Applications include treatment of various disease conditions including pressure ulcers, heart failure, high blood pressure, preeclampsia, osteoporosis, injuries of spine and to slow microgravity-induced bone and muscle loss. The systems and methods may be used to simulate gravity, weightlessness or buoyancy, in rehabilitation medicine. The system may include a chair, bed, a wearable suit or an exoskeleton.

An apparatus for health management includes an information collector configured to collect body composition information and characteristic information of a user, and a processor configured to determine a degree of muscle loss of the user based on the body composition information and the characteristic information of the user and provide a personalized health management program to the user based on the determined degree of muscle loss.

Described are compounds and methods useful in the promotion of muscle growth, the treatment of muscle loss or insufficient muscle growth, and the treatment of fibrotic conditions.

The present disclosure relates to a composition containing a Paeoniae radix extract as an active ingredient. The composition may alleviate inappetence, weight loss, muscle loss and fatigue and inhibit hematopoietic toxicity. Thus, the composition may be effectively used for the prevention, alleviation or treatment of cachexia and muscle loss.

The present invention relates to a composition for preventing or treating a muscle disorder, which includes a chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1α, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance. In addition, the present invention is a natural substance and may be safely used without a side effect, and therefore may be used as a medication, food or a cosmetic.

Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and / or low DHEA or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and a selective estrogen receptor modulator (SERM) (particularly acolbifene), an antiestrogen or a prodrug of the two. The symptoms or diseases are loss of libido, erectile dysfunction, tiredness, loss of energy, depression, bone loss, muscle loss, muscle weakness, fat accumulation, memory loss, cognition loss, Alzheimer's disease, dementia, loss of body hair, fertility problems, insomnia, gynecomastia, anemia, hot flushes, sweats, decreased sense of well-being, obesity, osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, cardiovascular disease and type 2 diabetes. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

The invention relates to a derivative of general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and / or prevention of muscle atrophy in mammals and / or to limit muscle atrophy in mammals and / or to stimulate muscle growth in mammals doing exercise and aiming to increase muscle mass and quality, as prevention against the onset of age-related symptoms of sarcopenia or for rehabilitation following muscle loss, muscle atrophy being related to age and / or to the consequences of drug treatment and / or immobilisation and / or cachexia.

The invention provides novel Wnt polypeptides that have enhanced solubility and improved biologic drug-like properties, and polynucleotides encoding the Wnt polypeptides of the invention. The Wnt polypeptides of the invention can be used therapeutically, such as, for example, in methods of preventing or treating muscle loss and / or promoting muscle hypertrophy and growth.